Balyasny Asset Management
TVRD

Balyasny Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Balyasny Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-5,278
Closed -$3.49M – 1810
2017
Q1 		$3.49M Buy
+5,278
New +$2.82M 0.02% 778

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Balyasny Asset Management's TVRD Position: Q4 2022 in Review

Balyasny Asset Management sold out of Tvardi Therapeutics (TVRD) in Q4 2022, closing a stake of 541 shares — an estimated $182K sold.

Balyasny Asset Management first reported a position in TVRD in Q1 2016 and held it in 9 quarters. The position peaked at $8.08M in Q2 2017. 160 funds tracked by Wall St. Rank hold TVRD as of Q4 2022.

  • Balyasny Asset Management reported no remaining Tvardi Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 541 Tvardi Therapeutics shares in Q4 2022, an estimated $182K.
  • Balyasny Asset Management first reported a position in Tvardi Therapeutics in Q1 2016 and held it in 9 quarters.
  • Balyasny Asset Management's Tvardi Therapeutics position peaked at $8.08M in Q2 2017.
  • 160 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.